The state of Nevada currently has 15 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Las Vegas, Henderson, Reno and Pahrump.
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Palm Research Center Inc-Vegas, Las Vegas, Nevada
Conditions: Diabetes Mellitus, Type 2, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Sierra Clinical Research, Las Vegas, Nevada +5 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Recruiting
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Healor Primary Care / CCT Research, Las Vegas, Nevada +1 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Wr-Crcn, Llc, Las Vegas, Nevada
Conditions: Type 2 Diabetes
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Las Vegas Medical Research, Las Vegas, Nevada
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Palm Research Center Tenaya, Las Vegas, Nevada +1 locations
Conditions: Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Recruiting
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/22/2024
Locations: Site 371, Las Vegas, Nevada
Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Renown Regional Medical Center, Reno, Nevada
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
Recruiting
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/13/2024
Locations: Jubilee Clinical Research, Inc., Las Vegas, Nevada
Conditions: Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
Recruiting
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/09/2024
Locations: Santa Rosa Medical Centers of Nevada, Las Vegas, Nevada
Conditions: Type 2 Diabetes Mellitus
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Palm Research Center Tenaya, Las Vegas, Nevada
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
Strawberries and Risk of Diabetes in Adults
Recruiting
Strawberries can be categorized as a functional food based on results from several clinical trials in improving cardiometabolic health beyond providing nutrition. Recent studies identify the role of strawberries in improving insulin resistance and risks of type 2 diabetes which urgently warrants further investigation, keeping in view the huge public health burden of diabetes in the US. In this study, the investigators propose to investigate the effects of a dietary achievable dose of strawberrie... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/29/2023
Locations: University of Nevada at Las Vegas, Las Vegas, Nevada
Conditions: PreDiabetes, Metabolic Syndrome